pfizer (australia) aciclovir intravenous infusion aciclovir 250mg/10ml injection ampoule
pfizer australia pty ltd - aciclovir -
pfizer (australia) leucovorin calcium folinic acid (as calcium folinate) 100mg/10ml injection usp ampoule
pfizer australia pty ltd - calcium folinate, quantity: 10.8 mg/ml (equivalent: folinic acid, qty 10 mg/ml) - injection, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; sodium chloride; water for injections - leucovorin calcium injection usp is indicated following high dose methotrexate therapy to reduce toxicity (leucovorin rescue). it is also indicated after inadvertent overdosage with methotrexate and in impaired methotrexate elimination.
pfizer (australia) leucovorin calcium folinic acid (as calcium folinate) 50mg/5ml injection usp ampoule
pfizer australia pty ltd - calcium folinate, quantity: 10.8 mg/ml (equivalent: folinic acid, qty 10 mg/ml) - injection, solution - excipient ingredients: water for injections; sodium hydroxide; sodium chloride; hydrochloric acid - leucovorin calcium injection usp is indicated following high dose methotrexate therapy to reduce toxicity (leucovorin rescue). it is also indicated after inadvertent overdosage with methotrexate and in impaired methotrexate elimination.
exemestane pfizer
pfizer australia pty ltd - exemestane -
exemestane pfizer
pfizer australia pty ltd - exemestane -
atorvastatin pfizer
pfizer australia pty ltd - atorvastatin calcium -
latanoprost pfizer
pfizer australia pty ltd - latanoprost -
exemestane pfizer
pfizer new zealand limited - exemestane 25mg - coated tablet - 25 mg - active: exemestane 25mg excipient: crospovidone hydrated silica hypromellose macrogol 6000 magnesium carbonate magnesium stearate mannitol methyl hydroxybenzoate polysorbate 80 polyvinyl alcohol powdered cellulose simeticone sodium starch glycolate sucrose titanium dioxide - · the adjuvant treatment of postmenopausal women with oestrogen receptor positive or receptor unknown early breast cancer after initial adjuvant tamoxifen to reduce the risk of recurrence (distant and loco-regional) and contralateral breast cancer · the treatment of advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy · the third-line hormonal treatment of advanced breast cancer in women with natural or induced postmenopausal status whose disease progressed following treatment with anti-oestrogens and either non-steroidal aromatase inhibitors or progestins.
pregabalin pfizer
upjohn eesv - pregabalin - anxiety disorders; epilepsy - antiepileptics, - neuropathic painpregabalin pfizer is indicated for the treatment of peripheral and central neuropathic pain in adults.epilepsypregabalin pfizer is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.generalised anxiety disorderpregabalin pfizer is indicated for the treatment of generalised anxiety disorder (gad) in adults.
pemetrexed pfizer (previously known as pemetrexed hospira uk limited)
pfizer europe ma eeig - pemetrexed ditromethamine - carcinoma, non-small-cell lung; mesothelioma - folic acid analogues, antimetabolites - malignant pleural mesotheliomapemetrexed hospira uk limited in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.non-small cell lung cancerpemetrexed hospira uk limited in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see smpc section 5.1).pemetrexed hospira uk limited is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see smpc section 5.1).pemetrexed hospira uk limited is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see smpc section 5.1).